Skip to main content
Clinical Trials/NCT04533152
NCT04533152
Recruiting
N/A

Prognostic Determinants in Patients With Diabetic Foot Ulcer (PDF Cohort) - A French Prospective Multicentre Cohort.

University Hospital, Bordeaux26 sites in 2 countries1,000 target enrollmentNovember 24, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Diabetic Foot Ulcer
Sponsor
University Hospital, Bordeaux
Enrollment
1000
Locations
26
Primary Endpoint
DFU risk score
Status
Recruiting
Last Updated
3 months ago

Overview

Brief Summary

The worse prognosis observed in patients with Diabetic Foot Ulcer (DFU) has not been fully understood. Poor prognosis may be related to other conditions (inflammation, infectious disease, cancers) further to cardiovascular disease.

The aim of the study is to conduct the first prospective, observational and multi-centre cohort of patients with DFU in France, in order to evaluate the 5-years mortality rate, its causes and relevant prognostic determinants.

Detailed Description

Diabetic foot ulcer (DFU) is one of the major complications frequently observed in patients with diabetes. DFU is the leading cause of non-traumatic lower-limb amputation (LLA), and it is associated with cognitive decline, worsening quality of life and substantial economic impact on French healthcare system. DFU is also associated with excess risk of premature death with significant decrease in life expectancy despite major improvement in medical care during last decades. The hypothesis of the study is that this worse prognosis seen in DFU patients may not be fully explained by a high cardiovascular risk, but mainly linked to different causes, including inflammatory, infectious and malignant conditions. In addition, to conduct the first prospective, observational and multi-centre cohort of patients with DFU in France to evaluate the 5-years mortality rate, its causes and relevant prognostic determinants, the investigators will also assess all changes in health-related quality of life (HRQoL), and the economic impact related to DFU (cost of illness study) for the French healthcare system, using SNDS claims databases. A 3-year inclusion period will start during 2020, and each participant will be followed for 5 years or until death.

Registry
clinicaltrials.gov
Start Date
November 24, 2021
End Date
November 1, 2029
Last Updated
3 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Bordeaux
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults with diabetes and DFU, defined as a foot skin ulceration or open LLA wound, measuring at least 5 mm of diameter, located below the malleolus, and induced by diabetic complications. In the case of an amputation before inclusion, the amputation stump will be considered as the main wound and not the wound that led to the amputation.

Exclusion Criteria

  • Acute or chronic lower-limb ischemia without open skin wound,
  • Foot infection without open skin wound,
  • Intercurrent disease prohibiting participation in an observational study,
  • Pregnancy or breastfeeding
  • Curatorship or guardianship
  • Prisoners -- Patient currently participating to more than one other clinical study (interventional or observational, 2 study maximum including PDF) or currently participating to another study interfering with standard care of diabetic foot

Outcomes

Primary Outcomes

DFU risk score

Time Frame: 5 years after inclusion

Construct a DFU risk score equation of all-death will be computed to determine individuals with the higher risk of worse outcomes.

Secondary Outcomes

  • Survival without active index DFU(At 3 and 12 months after inclusion day)
  • Survival without recurrent index DFU(At 12, 24, 36, 48, 60 months after inclusion day)
  • Survival without major adverse limb events (MALE)(5 years after inclusion)
  • Survival without major macrovascular events (MACE)(5 years after inclusion)
  • Survival without major microvascular events (MICE)(5 years after inclusion)

Study Sites (26)

Loading locations...

Similar Trials